{"pmid":32283245,"title":"SARS-COV-2 infection is likely to be androgen mediated.","text":["SARS-COV-2 infection is likely to be androgen mediated.","J Am Acad Dermatol","Wambier, Carlos Gustavo","Goren, Andy","32283245"],"journal":"J Am Acad Dermatol","authors":["Wambier, Carlos Gustavo","Goren, Andy"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283245","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jaad.2020.04.032","keywords":["5-alpha reductase","ACE2","Angiotensin Converting Enzyme 2","COVID-19","SARS-CoV-2","TMPRSS2","androgen receptor","androgenetic alopecia","anti-androgen therapy","dutasteride","finasteride","human skin","retinoids","transmembrane protease serine 2"],"source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1663989232688955393,"score":7.979339,"similar":[{"pmid":32142651,"pmcid":"PMC7102627","title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.","text":["SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.","The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.","Cell","Hoffmann, Markus","Kleine-Weber, Hannah","Schroeder, Simon","Kruger, Nadine","Herrler, Tanja","Erichsen, Sandra","Schiergens, Tobias S","Herrler, Georg","Wu, Nai-Huei","Nitsche, Andreas","Muller, Marcel A","Drosten, Christian","Pohlmann, Stefan","32142651"],"abstract":["The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention."],"journal":"Cell","authors":["Hoffmann, Markus","Kleine-Weber, Hannah","Schroeder, Simon","Kruger, Nadine","Herrler, Tanja","Erichsen, Sandra","Schiergens, Tobias S","Herrler, Georg","Wu, Nai-Huei","Nitsche, Andreas","Muller, Marcel A","Drosten, Christian","Pohlmann, Stefan"],"date":"2020-03-07T11:00:00Z","year":2020,"_id":"32142651","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.cell.2020.02.052","keywords":["ACE2","COVID-19","SARS-CoV-2","TMPRSS2","coronavirus","entry","neutralization","priming","spike"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1663352134185254912,"score":66.375496}]}